Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Cyclin D1 Driven CDK4 Activity Is Responsible for Hypersensitivity to NOXA Inducing Combination Treatment in Mantle Cell Lymphoma (MCL) Cells

Simon Heine, MSc, Elisabeth Silkenstedt, MD, Michael A Dengler, PhD, Kleih Markus, MSc, German Ott, MD, Neus Giménez Carabaza, B.Pharm, Colomer Dolors, PhD, Heiko van der Kuip, PhD, Walter E. Aulitzky, MD

Blood (2017) 130 (Supplement 1): 2811.

https://doi.org/10.1182/blood.V130.Suppl_1.2811.2811

Published: 2017

Journal Articles

Notch1 Signaling in NOTCH1 -Mutated Mantle Cell Lymphoma Depends on DLL4 and Is a Potential Target for Specific Antibody Therapy

Elisabeth Höring, MD, Berta Colom Sanmarti, Silvia Xargay-Torrent, PhD, Walter E Aulitzky, MD, Heiko van der Kuip, PhD, Elias Campo, Mónica López-Guerra, PhD, Dolors Colomer, PhD

Blood (2016) 128 (22): 1846.

https://doi.org/10.1182/blood.V128.22.1846.1846

Published: 2016

Journal Articles

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases

Yashodhara Dasgupta, Mateusz Koptyra, Grazyna Hoser, Kanchan Kantekure, Darshan Roy, Barbara Gornicka, Margaret Nieborowska-Skorska, Elisabeth Bolton-Gillespie, Sabine Cerny-Reiterer, Markus Müschen, Peter Valent, Mariusz A. Wasik, Christine Richardson, Oliver Hantschel, Heiko van der Kuip, Tomasz Stoklosa, Tomasz Skorski

Blood (2016) 127 (17): 2131–2143.

https://doi.org/10.1182/blood-2015-11-681171

Published: 2016

Includes: Supplemental data

Journal Articles

Dual Targeting of NOXA/MCL-1 Synergistically Induces Cell Death in Mantle Cell Lymphoma (MCL) Cells

Elisabeth Höring, German Ott, MD, Christine Bayha, Kleih Markus, Matthias C. Voehringer, MD, Heiko van Der Kuip, Walter E. Aulitzky, MD

Blood (2015) 126 (23): 2757.

https://doi.org/10.1182/blood.V126.23.2757.2757

Published: 2015

Journal Articles

The Phenotype High Noxa mRNA/Low NOXA Protein Levels Constitutes a Critical Achilles Heel Of Mantle Cell Lymphoma (MCL) Cells

Michael A. Dengler, Andrea Weilbacher, Matthias Gutekunst, Annette M. Staiger, Heike Horn, German Ott, MD, Heiko van der Kuip, Walter E. Aulitzky

Blood (2013) 122 (21): 644.

https://doi.org/10.1182/blood.V122.21.644.644

Published: 2013

Journal Articles

Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

Blood (2012) 119 (18): 4253–4263.

https://doi.org/10.1182/blood-2011-10-385658

Published: 2012

Includes: Supplemental data

Journal Articles

Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells

Blood (2011) 118 (21): 2736.

https://doi.org/10.1182/blood.V118.21.2736.2736

Published: 2011

Journal Articles

Cyclin D1 Over-Expressing Mantle Cell Lymphoma Cells Are Hypersensitive to Inhibition of Fatty Acid Synthase (FASN)

Michael A. Dengler, Matthias Gutekunst, Stephanie Kopacz, Heike Horn, Ute Hofmann, Matthias Schwab, German Ott, MD, Heiko van der Kuip, Walter E. Aulitzky

Blood (2011) 118 (21): 1656.

https://doi.org/10.1182/blood.V118.21.1656.1656

Published: 2011

Journal Articles

Glucocorticoids Inhibit Cell Death Induced by Oncogenic Stress After Imatinib Withdrawal In TKI Resistant p190Bcr/Abl Overexpressing Cells

Michael A. Dengler, Annette M. Staiger, Ute Hofmann, Matthias Gutekunst, Heiko van der Kuip, Walter E. Aulitzky, MD

Blood (2010) 116 (21): 3150.

https://doi.org/10.1182/blood.V116.21.3150.3150

Published: 2010

Journal Articles

Combination of Imatinib with Cisplatin and Nutlin-3: Functional and Molecular Effects on Bcr-Abl Positive Cells.

Ioanna Skorta, Heiko van der Kuip, Martin Henkes, Moshe Oren, Walter E. Aulitzky

Blood (2007) 110 (11): 2954.

https://doi.org/10.1182/blood.V110.11.2954.2954

Published: 2007

Journal Articles

Dominant Negative Effect of Kinase-Inactive Bcr-Abl on Cell Survival and DNA Damage Response Pathways in Imatinib-Treated Cells.

Heiko van der Kuip, PhD, Fabienne Fiesel, Alexandra Moehring, Walter E. Aulitzky, MD

Blood (2005) 106 (11): 2887.

https://doi.org/10.1182/blood.V106.11.2887.2887

Published: 2005

Journal Articles

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor

Nikolas von Bubnoff, Darren R. Veach, Heiko van der Kuip, Walter E. Aulitzky, Jana Sänger, Petra Seipel, William G. Bornmann, Christian Peschel, Bayard Clarkson, Justus Duyster

Blood (2005) 105 (4): 1652–1659.

https://doi.org/10.1182/blood-2004-06-2445

Published: 2005

Journal Articles

A Cell-Based Screening Method for Resistance of Bcr-Abl Positive Leukemia Identifies the Mutation Pattern for an Alternative Abl Kinase Inhibitor.

Nikolas von Bubnoff, M.D., Darren R. Veach, Ph.D., Heiko van der Kuip, Ph.D., Walter E. Aulitzky, M.D., Jana Saenger, Petra Seipel, William G. Bornmann, Ph.D., Christian Peschel, M.D., Bayard Clarkson, M.D., Justus Duyster, M.D.

Blood (2004) 104 (11): 558.

https://doi.org/10.1182/blood.V104.11.558.558

Published: 2004

Journal Articles

Repeated Application of Sequence-Specific SiRNA Molecules Leads to an Effective Downmodulation of All Clinically Relevant bcr-abl Gene Variants.

Lara Wohlbold, Heiko van der Kuip, Alexandra Moehring, Galit Granot, Dr, Moshe Oren, Prof Dr, Hans-Peter Vornlocher, Dr, Walter E. Aulitzky

Blood (2004) 104 (11): 4319.

https://doi.org/10.1182/blood.V104.11.4319.4319

Published: 2004

Journal Articles

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)

Lara Wohlbold, Heiko van der Kuip, Cornelius Miething, Hans-Peter Vornlocher, Cornelius Knabbe, Justus Duyster, Walter E. Aulitzky

Blood (2003) 102 (6): 2236–2239.

https://doi.org/10.1182/blood-2002-12-3899

Published: 2003

Journal Articles

Adhesion to fibronectin selectively protects Bcr-Abl + cells from DNA damage–induced apoptosis

Heiko van der Kuip, Alexander W. Goetz, Cornelius Miething, Justus Duyster, Walter E. Aulitzky

Blood (2001) 98 (5): 1532–1541.

https://doi.org/10.1182/blood.V98.5.1532

Published: 2001

Journal Articles

Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines

Tarja Jonuleit, Heiko van der Kuip, Cornelius Miething, Heike Michels, Michael Hallek, Justus Duyster, Walter E. Aulitzky

Blood (2000) 96 (5): 1933–1939.

https://doi.org/10.1182/blood.V96.5.1933

Published: 2000

NARROW

Cyclin D1 Driven CDK4 Activity Is Responsible for Hypersensitivity to NOXA Inducing Combination Treatment in Mantle Cell Lymphoma (MCL) Cells

Notch1 Signaling in NOTCH1 -Mutated Mantle Cell Lymphoma Depends on DLL4 and Is a Potential Target for Specific Antibody Therapy

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases

Dual Targeting of NOXA/MCL-1 Synergistically Induces Cell Death in Mantle Cell Lymphoma (MCL) Cells

The Phenotype High Noxa mRNA/Low NOXA Protein Levels Constitutes a Critical Achilles Heel Of Mantle Cell Lymphoma (MCL) Cells

Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells

Cyclin D1 Over-Expressing Mantle Cell Lymphoma Cells Are Hypersensitive to Inhibition of Fatty Acid Synthase (FASN)

Glucocorticoids Inhibit Cell Death Induced by Oncogenic Stress After Imatinib Withdrawal In TKI Resistant p190Bcr/Abl Overexpressing Cells

Combination of Imatinib with Cisplatin and Nutlin-3: Functional and Molecular Effects on Bcr-Abl Positive Cells.

Dominant Negative Effect of Kinase-Inactive Bcr-Abl on Cell Survival and DNA Damage Response Pathways in Imatinib-Treated Cells.

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor

A Cell-Based Screening Method for Resistance of Bcr-Abl Positive Leukemia Identifies the Mutation Pattern for an Alternative Abl Kinase Inhibitor.

Repeated Application of Sequence-Specific SiRNA Molecules Leads to an Effective Downmodulation of All Clinically Relevant bcr-abl Gene Variants.

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)

Adhesion to fibronectin selectively protects Bcr-Abl + cells from DNA damage–induced apoptosis

Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only